{"entity":{"id":"excellthera","kind":"company","name":"ExCellThera","aka":["ExCellThera Inc."],"tldr":"ExCellThera is a Montreal cell-therapy company that uses the small molecule UM171 to multiply blood stem cells from cord blood, making transplants possible for patients who would otherwise lack a donor.","summary":"ExCellThera was spun out of Université de Montréal around UM171, a molecule discovered in Guy Sauvageau's laboratory that expands haematopoietic stem cells in culture. Its product, dorocubicel (ECT-001, UM171-expanded cord blood), lets a small cord blood unit be grown into a graft for adults with high-risk blood cancers who lack a matched donor. Phase 2 trials in acute leukaemia and myelodysplastic syndromes have reported low rates of chronic graft-versus-host disease and relapse.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.excellthera.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["dorocubicel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Montreal","country":"CA","companyType":"cell-therapy","website":"https://www.excellthera.com/","founded":2015,"investors":[],"funding":[]},"route":"/companies/excellthera/","neighbours":{"drug":[{"id":"dorocubicel","kind":"drug","name":"Dorocubicel (UM171-expanded cord blood)","route":"/drugs/dorocubicel/"}]}}